Lixte Biotechnology (NMAD) Financials

Lixte Biotechnology Holdings (NASDAQ: NMAD) remains a pre-revenue biotechnology company with substantial operating losses and recurring cash burn. The latest filing identifies the company as Nomad Power Solutions, Inc., while earlier filings identify Lixte Biotechnology Holdings, Inc.; investors should verify the company’s current corporate name and business status.

Positive developments: Cash and equivalents increased to $12.7 million at June 30, 2026, from $3.3 million at March 31, 2026, and $2.9 million at September 30, 2025. Total assets also rose to $26.6 million from $10.9 million in the prior quarter. The balance sheet shows relatively low liabilities of $1.7 million, providing a sizable asset cushion compared with obligations.

• The company raised approximately $16.4 million through common-equity issuance during the second quarter of 2026, substantially improving near-term liquidity.
• Cash flow from operations improved modestly from a $1.83 million outflow in Q1 2026 to a $1.61 million outflow in Q2, although operations remain cash negative.
• Total liabilities declined slightly to $1.66 million in Q2 2026 from $1.69 million in Q1, and liabilities remain modest relative to total assets.
• The company reported a $6.5 million note and lease receivable in Q2 2026, creating a potentially valuable balance-sheet asset if collectible and realizable as reported.

Key items to monitor: The company has reported no operating revenue in the provided quarters. As a result, its financial position depends heavily on equity financing, asset transactions and other non-operating sources of cash rather than an established commercial business.

• The latest $12.7 million cash balance would cover roughly eight quarters of Q2 operating cash burn if spending remained constant, but this is only a simple estimate and excludes research, transaction, working-capital and financing needs.
• Q2 investing cash flow was negative $6.5 million, approximately matching the new note and lease receivable; the economic nature and collectability of this transaction warrant additional review.
• Research and development expense was $62,250 in Q2 2026, down sharply from $333,376 in Q1, while selling, general and administrative expense increased to $2.29 million from $1.65 million. This indicates that quarterly spending is volatile and increasingly concentrated in administrative costs.

Risks for investors: Losses have persisted throughout the reported period, and the company has not demonstrated revenue generation or operating profitability. Q2 2026’s net loss attributable to common shareholders was $2.19 million, compared with $1.94 million in Q1 and $2.56 million in Q4 2025. The company’s accumulated deficit also reached $62.2 million.

• Revenue has remained at $0 in every income statement provided from 2023 through Q2 2026, leaving no evidence of a functioning revenue stream or commercial scale.
• Operating expenses have generally risen from approximately $613,000 in Q4 2024 to $2.35 million in Q2 2026, while operating losses have widened to $2.35 million in the latest quarter.
• Operating cash flow has been negative in every provided quarter, including outflows of $1.61 million in Q2 2026, $1.83 million in Q1 2026 and $1.09 million in Q4 2025.
• The sharp increase in common stock and weighted-average shares outstanding indicates significant dilution. Weighted-average basic shares increased from 2.25 million in much of 2024 to 13.48 million in Q2 2026, and additional equity financing may be required if losses continue.

Overall, the latest financing materially strengthened liquidity and reduced immediate balance-sheet pressure, but the improvement was driven by equity issuance rather than operating progress. Until NMAD produces revenue, reduces its cash burn or establishes a sustainable financing plan, the stock remains highly dependent on investor funding and vulnerable to further dilution.